je.st
news
Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), for the Treatment of Advanced Prostate Cancer
2015-04-08 13:30:05| Merck.com - Product News
Dateline City: PRINCETON, N.J., and KENILWORTH, N.J. KEYNOTE-046 is the second trial initiated to evaluate KEYTRUDA, and the first-in-human study of ADXS-PSA, for prostate cancer Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA (ADXS31-142), an investigational Lm-LLO immunotherapy, and KEYTRUDA (pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). Language: English read more
Tags: the
of
advanced
study
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||